Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises CMA Microdialysis in connection with the sale of pre-clinical business
Mandate

Vinge advises CMA Microdialysis in connection with the sale of pre-clinical business

July 04, 2011

Vinge has advised CMA Microdialysis in connection with the sale of its pre-clinical business to Harvard Biosciences. The main shareholders of MCA Microdialysis are Investor Growth Capital and Bure Equity. In connection with the transaction, the company has changed its name to Dipylon Medical.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, fellow partner Fredrik Dahl and associate Claes Henriksson.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

 Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

 Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026